Enoxaparin sodium
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Arthroplasty, Replacement, Hip
Conditions
Arthroplasty, Replacement, Hip
Trial Timeline
Jun 1, 2006 → —
NCT ID
NCT00349180About Enoxaparin sodium
Enoxaparin sodium is a phase 3 stage product being developed by Sanofi for Arthroplasty, Replacement, Hip. The current trial status is completed. This product is registered under clinical trial identifier NCT00349180. Target conditions include Arthroplasty, Replacement, Hip.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00349180 | Phase 3 | Completed |
| NCT00077844 | Phase 2/3 | Completed |
| NCT00077805 | Approved | Completed |
| NCT00077818 | Approved | Completed |
| NCT00077753 | Approved | Completed |
Competing Products
9 competing products in Arthroplasty, Replacement, Hip
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| DU-176b | Daiichi Sankyo | Phase 2 | 52 |
| YM150 + Warfarin | Astellas Pharma | Phase 2 | 52 |
| Tapentadol IR (CG5503) + Placebo + Oxycodone HCL IR + Tapentadol IR (CG5503) | Johnson & Johnson | Phase 3 | 77 |
| Zoledronic acid 5mg | Novartis | Approved | 85 |
| Denosumab | Amgen | Phase 2 | 51 |
| JNJ-70033093 25 mg + JNJ-70033093 50 mg + JNJ-70033093 100 mg + JNJ-70033093 200 mg + Placebo + Enoxaparin 40 mg | Bristol Myers Squibb | Phase 2 | 51 |
| 48-hour ropivacaine infusions + Single dose ropivacaine + Patient controlled analgesics | Sanofi | Pre-clinical | 22 |
| Enoxaparin + Apixaban + BAY1213790 | Bayer | Phase 2 | 49 |
| Rivaroxaban (Xarelto, BAY59-7939) | Bayer | Pre-clinical | 20 |